PARSIPPANY, NJ--(Marketwire - 08/06/10) - The Medicines Company today announced that the U.S. Patent and Trademark Office (PTO) has granted a one-year interim extension of the term of U.S. Patent No. 5,196,404, the principal U.S. patent that covers Angiomax, until August 13, 2011.
The PTO routinely grants such interim extensions when required to provide time to process innovators’ applications for patent term extension under the Hatch Waxman Act.
The Company expects the new patent expiry date to be listed in the FDA “Orange Book.”
A copy of the interim extension order is available on the Company’s website: http://www.themedicinescompany.com
About The Medicines Company The Medicines Company (NASDAQ:MDCO - News) is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable.
Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words “believes,” “anticipates” and “expects” and similar expressions, including the Company’s preliminary revenue results, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include the extent of the commercial success of Angiomax, the Company’s ability to develop its global operations and penetrate foreign markets, whether the Company’s products will advance in the clinical trials process on a timely basis or at all, whether the Company will make regulatory submissions for product candidates on a timely basis, whether its regulatory submissions will receive approvals from regulatory agencies on a timely basis or at all, whether physicians, patients and other key decision makers will accept clinical trial results, risks associated with the establishment of international operations, and such other factors as are set forth in the risk factors detailed from time to time in the Company’s periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company’s Quarterly Report on Form 10-Q filed on May 10, 2010, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.
Contact: Michael Mitchell Investor Relations The Medicines Company 973-290-6000 investor.relations@themedco.com
